Dianthus Therapeutics (DNTH) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 104.0% versus a loss of 65.1%. Over five years, IONS leads with a -8.5% price change compared with -12.8% for DNTH. Dianthus Therapeutics is the larger company by market cap ($4.76 billion vs $4.43 billion), about 1.1 times the size, while Ionis Pharmaceuticals is growing revenue faster (+33.8% vs -67.3%).
Ionis Pharmaceuticals converts more of its revenue into profit, with a net margin of -40.4% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | IONS |
|---|---|---|
| Share price | $84.55 | $26.58 |
| Market cap | $4.76B | $4.43B |
| 1-day change | -0.33% | -2.35% |
| YTD return | +105.17% | -66.40% |
| 1-year return | +103.98% | -65.07% |
| 5-year return | -12.80% | -8.50% |
| EPS (TTM) | $-4.08 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $943.71M |
| Revenue growth (YoY) | -67.35% | +33.83% |
| Net income (latest FY) | $-162.34M | $-381.39M |
| Gross margin | — | 98.31% |
| Operating margin | -8739.34% | -40.45% |
| Net margin | -7973.33% | -40.41% |
| 52-week high | $117.88 | $86.74 |
| 52-week low | $35.84 | $26.53 |
| Distance from 52-week high | -28.27% | -69.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +64.70% | +155.19% |
| Average volume | 848.96K | 3.91M |
| Shares outstanding | 56.31M | 166.55M |
| Employees | 92 | 1,485 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed IONS by 169.0 percentage points over the past year.
- Ionis Pharmaceuticals is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- Ionis Pharmaceuticals grew revenue faster in its latest fiscal year (+33.83% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees
DNTH vs IONS FAQ
Which is bigger, Dianthus Therapeutics or Ionis Pharmaceuticals?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.76B compared with $4.43B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, DNTH or IONS?
DNTH returned +103.98% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Ionis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.